Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04713787 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Safety and Efficacy Study of Different Doses of Oxfendazole Compared to a Single Dose of Albendazole to Treat Trichuris Trichiura Infection in Adults

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 1 month later Jan 30, 2026 → Feb 28, 2027
See other at-risk trials from Asociacion Benefica Prisma

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jan 30, 2026 to Feb 28, 2027
    • Study completion pushed from Jun 30, 2026 to May 30, 2027
    • Site details revised
    v32
  2. Minor Eligibility criteria expanded, about 12 wordsv31
  3. Notable Trial status: Not Yet Recruiting to Recruitingv30 Show 4 more changesShow less
    • Start date changed from estimate of Oct 1, 2023 to Sep 7, 2024
    • Primary completion date: Oct 1, 2025 to Jan 30, 2026
    • Study completion date: Dec 1, 2025 to Jun 30, 2026
    • Study site revised
  4. Notable Primary completion date: Oct 1, 2023 to Oct 1, 2025
    • Start date: Sep 8, 2021 to Oct 1, 2023
    • Study completion date: Mar 1, 2024 to Dec 1, 2025
    v29
  5. Notable Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID) to Asociacion Benefica Prisma
    • Start date: Jul 8, 2021 to Sep 8, 2021
    • Collaborators: 1 to 4
    v28
Show 26 earlier versionsHide 26 earlier versions
  1. Minor 2 versions Re-verified since Jul 1, 2021, no change to tracked fieldsv26-v27
  2. Minor Collaborators expanded, about 6 wordsv25
  3. Minor Collaborators shortened, about 6 wordsv24
  4. Notable Start date: Jun 3, 2021 to Jul 8, 2021v23
  5. Minor 2 versions Re-verified since Jun 3, 2021, no change to tracked fieldsv21-v22
  6. Minor Study sites: 2 to 1v20
  7. Minor Study sites: 1 to 2v19
  8. Notable Start date: May 1, 2021 to Jun 3, 2021v18
  9. Minor 10 versions Re-verified since Mar 4, 2021, no change to tracked fieldsv8-v17
  10. Notable Primary completion date: Jul 1, 2021 to Oct 1, 2023v7 Show 5 more changesShow less
    • Start date: Mar 11, 2021 to May 1, 2021
    • Enrollment target: 250 to 249
    • Study completion date: Jul 1, 2021 to Mar 1, 2024
    • Study description expanded, about 21 words
    • Study arms: 5 to 3
  11. Notable Start date: Feb 4, 2021 to Mar 11, 2021
    • Collaborators expanded, about 6 words
    v6
  12. Minor Re-verified, no change to tracked fieldsv5
  13. Minor Study site revisedv4
  14. Minor Re-verified, no change to tracked fieldsv3
  15. Minor Study sites: 2 to 1v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 2 trial to evaluate the efficacy of different doses of oxfendazole versus a single dose of albendazole in curing or reducing the egg burden in subjects with T. trichiura infections. 249 subjects will be randomized in a 1:1:1 ratio to one of three dose-groups to receive a single dose of oxfendazole 400 mg or 800 mg, or a single dose of albendazole 400 mg. The study team members and study subjects will not be blinded to the dose group. However, the laboratory assessors evaluating the stool samples will be blinded. Subjects will be recruited in Iquitos, Peru, and surrounding villages where there is a high prevalence of T. trichiura infection. Subjects will be solicited through town hall meetings and local clinics and through recommendations from local care providers. A two-stage screening process will be utilized. If subjects are found on the screening stool exam to have only a stool parasite other than T. trichuria or if the subject chooses not to participate in the study, the subject will be referred to a local health provider. If stool analysis performed at the end of the study period demonstrates stool parasites, the subjects will be contacted and referred to their local health provider where they will receive standard of care treatment. The primary objective is to assess the cure rate of different dose regimens of oxfendazole vs. albendazole in the treatment of T. trichiura infections using the Kato-Katz stool examination method.
Trial Details
NCT Number NCT04713787
Lead Sponsor Asociacion Benefica Prisma
Collaborators: Policlinico Asociacion Benefica PRISMA-Laboratorio Satelite IQTLAB, National Institutes of Health (NIH), University of Iowa, University of Virginia
Conditions
(from sponsor)
Trichuriasis
Related terms Trichuriasis
Enrollment 249 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov